Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) today and set a price target of ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...

Our writer thinks these two speculative shares offer high long-term growth potential from where they currently sit in the ...

Vertex Pharmaceuticals ( VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before ...